[Copper-zinc superoxide dismutase activity in platelets in patients with depressive disorder treated by fluoxetine--preliminary study].

What Was Tested

This controlled clinical trial looks at Fluoxetine.

The aim considering CuZnSOD participation in the neuroprotective mechanism and occurrence of neurodegenerative changes.

Why It Was Studied

Depressive disorder is still a rising and important clinical problem in the modern world.

The last decade studies paid attention to the theory different than momoaminergic hypothesis.

Who Took Part

According to the abstract, 20 people were involved.

By PubMed's age tags, the people studied were adults, both men and women.

How the Study Was Run

The researchers set it up as a pilot study.

It is described as a pilot, a small early test of whether a larger Fluoxetine study would be practical.

The study comprised of 32 persons treated due to depressive disorders.

The control group consisted of 20 people.

The activity of CuZnSOD was measured by Misra and Fridovich's method.

What Was Measured

PubMed files the paper under topics including Antidepressive Agents, Second-Generation, Blood Platelets, Major Depressive Disorder, Fluoxetine, Pilot Projects and Superoxide Dismutase.

What This Means in Plain Language

The paper is a pilot study of Fluoxetine in 20 people.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego), a journal based in Poland.

More context: all human trials.